Courtney D. DiNardo, MD, MSCE

Courtney D. DiNardo, MD, clinical researcher in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the current treatment landscape for patients with 

-mutated acute myeloid leukemia (AML) and how potential doublet and triplet combinations may play a role in this setting.

 mutations occur in about 6% to 15% of all patients with AML, says DiNardo, which makes this subgroup a sizable minority in AML. These patients tend to be older and are usually either not appopriate for or are not benefiting from standard intensive chemotherapy, so there is a lot of interest in finding more tolerable and efficacious regimens for 

The FDA approved an IDH inhibitor, ivosidenib (Tibsovo), as well as the combination of venetoclax (Venclexta) plus azacitidine (CC-486), which is a separate, more broad treatment option for patients with AML but has shown responses in 

The question now is when you have these different treatment options, how should these agents be used? DiNardo questions whether ivosidenib could be given with venetoclax, which could be a well-tolerated oral regimen given in the outpatient setting, or should all 3 agents, including ivosidenib, venetoclax, and azacitidine, be given together to improve the outcomes that have been observed with each of these therapies.

<< View more resources and information regarding AML

Videos

Courtney D. DiNardo, MD, discusses the current treatment landscape for patients with IDH1-mutated acute myeloid leukemia and how potential doublet and triplet combinations may play a role in this setting.

Expert Explores Potential Role of Doublets and Triplets in IDH1-Mutant Acute Myeloid Leukemia

Courtney D. DiNardo, MD, MSCE, a clinical researcher at The University of Texas MD Anderson Cancer Center, discusses what is on the horizon for the acute myeloid leukemia (AML) setting.

DiNardo thinks that incorporating enasidenib (Idhifa) plus azacitidine (Vidaza) into the standard of care for older patients with AML and

mutations is the next step for this patient population. On a broader scale, ensuring that mutational profiling for any patients with AML is coming back within a reasonable amount of time, which is about a week for DiNardo, so physicians can use a targeted inhibitor as frontline treatment for these patients.

Identifying whether or not there is a role for venetoclax (Venclexta) in combination with enasidenib and azacitidine in newly diagnosed patients with AML is also pertinent at the moment since both those drugs have shown to be effective with venetoclax separately in that setting, according to DiNardo. Figuring out if all 3 drugs, which are changing the standard of care for AML, will work better together without increasing toxicity for patients is an important question in this space.

Courtney D. DiNardo, MD, MSCE, discusses what is on the horizon for the acute myeloid leukemia setting.

Deciding the Next Steps for Treating Patients With Acute Myeloid Leukemia

Courtney D. DiNardo, MD, MSCE, an assistant professor in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, explains the rationale for the phase II AG221-AML-005 trial.

For the older population of patients with acute myeloid leukemia (AML), the current standard of care in the United States is azacitidine (Vidaza). The drug can lead to a complete remission rate of about 20%, an overall response rate of about 30%, and overall survival of around 12 months, says DiNardo.

The IDH2 inhibitor enasidenib (Idhifa) has been approved for the treatment of relapsed/refractory

-mutated AML, and it&rsquo;s promising activity in this patient population raised the question of whether patients who were newly diagnosed with

-mutant AML could derive benefit from enasidenib in combination with azacitidine.

https://www.targetedonc.com/news/enasidenib-plus-azacitidine-expands-treatment-landscape-for-idh2mutant-aml

Courtney D. DiNardo, MD, MSCE, explains the rationale for the phase II AG221-AML-005 trial.

Courtney D. DiNardo, MD, MSCE | Authors

Articles

Expert Explores Potential Role of Doublets and Triplets in IDH1-Mutant Acute Myeloid Leukemia

Deciding the Next Steps for Treating Patients With Acute Myeloid Leukemia

Combining Azacitidine/Enasidenib to Enhance the Treatment of Newly Diagnosed IDH2-Mutant AML